FDA approves Lupin’s Corgard generic
SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s generic version of Corgard (nadolol) tablets. The drug is indicated to manage patients with angina pectoris and to treat hypertension.
Lupin’s generic will be available in 20-, 40- and 80-mg dosage strengths. The drug had U.S. sales of $109.8 million for the 12 months ended June 2017, according to QuintilesIMS data.
NACDS, ASTHO and APHA workshop will explore building public health partnerships
ARLINGTON, Va. — The National Association of Chain Drug Stores is partnering with the Association of State and Territorial Health Officials and the American Public Health Association to host a workshop about building partnerships across public health agencies and pharmacies. The workshop, slated for Nov. 4, will take place ahead of the American Public Health Association Annual Meeting.
“NACDS is extremely pleased to be able to collaborate on this workshop,” NACDS president and CEO Steve Anderson said. “As the face of neighborhood healthcare, pharmacies and pharmacists offer convenient and accessible patient-centered services every day. This workshop encourages the important coordination between pharmacies and public health partners to significantly improve patient health outcomes, access to care and preparedness efforts.”
The workshop will offer pharmacy stakeholders the opportunity to hear from panelists from health departments, the pharmacy industry and the Centers for Disease Control and Prevention on such topics as preventive health, chronic disease, hypertension and public health preparedness.
“Pharmacy’s long-time commitment to improving the public’s health lead to the development of the Pharmacy Special Primary Interest Group within the 25,000-member American Public Health Association,” APHA’s Pharmacy SPIG founding chare Stuart Feldman said. “Currently, our 250 members give pharmacy a seat at the public health association table and the opportunity to advance pharmacy-public health partnerships throughout the diverse public health community. The workshop provides an opportunity for participants to learn about how these collaborations can demonstrate the value pharmacy brings to public health and in turn to the public’s health.”
The free workshop will take place at the Omni Atlanta Hotel at Atlanta’s CNN Center. Registration is currently open.
AmerisourceBergen’s Lash Group unveils Fusion to power patient support
FORT MILL, S.C. — AmerisourceBergen’s Lash Group this week unveiled Fusion, a new tech ecosystem for patient support. Fusion is designed to go beyond being a customer relationship management platform, bringing together technologies with workflows customized for patients support services, and offering a proprietary advanced data model that lets the Lash Group provide patients, providers and manufacturers a personalized experience, the company said.
“Pharmaceutical manufacturers face a growing array of new challenges in the market. Intense competition, rising commercialization costs, disaggregated data, consumerism and a shift to value-based care are key issues that complicate the commercialization process,” AmerisourceBergen group president global commercialization services and animal health Jim Cleary said. “Fusion enables Lash Group to provide greater support to manufacturers, while also increasing efficiency and providing a more comprehensive set of services throughout the patient journey and product lifecycle.”
Fusion was developed to streamline administrative tasks through to speed access to treatment, using artificial intelligence for benefit verification and leveraging multichannel communication capabilities to remove common barriers to therapy. Fusion also looks to create a simpler set of patient-provider interactions through such features as computer-telephony integration. And the platform can generate actionable insights for manufacturers through data management, real-time reports and dashboards, as well as targeted analytics, competitive intelligence and a more holistic view of the patient experience, the company said.
“There is no stronger example of AmerisourceBergen’s commitment to innovation and our ability to develop and deploy technologies that advance healthcare than Fusion,” AmerisourceBergen chief information officer Dale Danilewitz said. “By combining Lash Group’s high-tech, smart-touch service model with dozens of proven tools and the company's deep expertise across life sciences, we’re producing a seamless, end-to-end experience for manufacturers, providers and most importantly, patients.”